Taysha Gene Therapies, Inc.TSHANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -62.33% | -43.90% | -32.51% | +78.60% | -100.00% |
| Gross Profit Growth | -59.50% | -43.90% | -32.51% | +78.60% | -116.00% |
| EBITDA Growth | +0.00% | -137.81% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -139.35% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -135.90% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -135.90% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +113.06% | +9.62% | +16.46% | +27.99% | +31.92% |
| Weighted Average Shares Diluted Growth | +113.06% | +9.62% | +16.46% | +27.99% | +31.92% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -7.94% | -7.16% | -9.57% | +66.34% | +75.65% |
| Book Value per Share Growth | +0.00% | -12.93% | -12.20% | +78.50% | +86.95% |
| Debt Growth | +5.66% | +3.39% | +1.07% | +3.25% | +10.47% |
| R&D Expense Growth | +26.76% | +20.84% | -24.65% | +33.62% | +70.34% |
| SG&A Expenses Growth | -4.31% | -1.34% | +15.16% | +17.17% | +4.77% |